Global markets are being pulled in different directions by inflation headlines, shifting central bank signals, and energy and trade data, so it is no surprise that many investors are focusing on companies where analysts still see solid earnings growth potential and reasonably sound balance sheets. The Healthy high growth potential screener filters for exactly that, highlighting stocks that analysts expect to grow earnings over the next 3 years while meeting basic financial strength checks. In this article, you will see 3 of the strongest looking stocks from this screener and how they might fit into a growth-focused watchlist.

Kulicke and Soffa Industries (KLIC)

Overview: Kulicke and Soffa Industries designs and sells equipment and consumables that help chipmakers and electronics manufacturers assemble semiconductor devices, LEDs and sensors, with four main product lines spanning ball and wedge bonding tools, advanced packaging systems and aftermarket services.

Operations: Most revenue comes from Ball Bonding Equipment at about US$437.5m, followed by Aftermarket Products & Services at roughly US$166.7m, Advanced Solutions at around US$68.6m, Wedge Bonding Equipment at about US$76.4m and a smaller All Others segment at roughly US$19.0m.

Market Cap: US$6.4b

Kulicke and Soffa Industries is attracting attention because it sits at the crossroads of advanced chip packaging, high bandwidth memory and power electronics for EVs and clean energy, with recent quarterly sales above US$240m and a swing from loss to profit as demand for AI related products gains traction. At the same time, the stock trades on a very high P/E multiple, insiders have been selling after a sharp share price run and funding relies on higher risk external borrowings. As a result, expectations are already elevated and execution on new products like Fluxless thermocompression and vertical wire needs to be flawless. Investors who want to understand how this balance of fast growth, rich valuation and real operational risk stacks up are missing a crucial piece of the story here.

Kulicke and Soffa Industries looks like an earnings acceleration story priced for perfection, so the real question is whether expectations overshoot reality, and how the analyst forecasts for Kulicke and Soffa Industries might reveal the twist investors are missing

Seagate Technology Holdings (STX)

Overview: Seagate Technology Holdings provides data storage hardware and infrastructure, from high capacity hard drives and solid state drives for cloud and AI data centers to external drives for consumers and creative professionals, as well as its Lyve platform that links on premise and cloud storage.

Operations: Seagate generates about US$11.0b in revenue primarily from manufacturing and distributing storage solutions, with key markets including the United States at roughly US$5.4b, Singapore at about US$4.5b and the Netherlands at around US$1.1b.

Market Cap: US$242.1b

Investors are paying attention to Seagate Technology Holdings because it sits at the heart of the AI and cloud build out, with its HAMR based Mozaic drives and nearline products positioned for data center demand while management focuses on pricing discipline and cash generation. Earnings growth, strong margins and high analyst expectations all point to a company that could convert this demand into sizable cash flows, yet the stock already trades on a very rich P/E multiple, carries meaningful debt and faces competition from SSD and NAND technologies alongside potential tax and trade policy headwinds. The key consideration is how this mix of powerful growth drivers and financial risk is reflected in the detailed forecasts and valuation work that analysts have already done on Seagate.

Seagate Technology Holdings appears to be an AI storage heavyweight with cash flow potential that may be obscured by its headline debt and a relatively high P/E ratio. The more detailed story is available in the analysis report for Seagate Technology Holdings.

Legend Biotech (LEGN)

Overview: Legend Biotech develops cell therapies for cancer, led by its CAR-T treatment for multiple myeloma, and partners with large pharmaceutical companies to bring these products to patients in the United States, China and Europe.

Operations: Legend Biotech currently generates about US$1.1b of revenue entirely from biotechnology, with roughly US$856.9m from the United States, US$28.1m from China and US$254.0m from other regions.

Market Cap: US$5.2b

Legend Biotech interests many growth focused investors because it combines a commercial CAR-T therapy, CARVYKTI, with a broader pipeline that includes in vivo and off the shelf cell therapies backed by encouraging early data in blood cancers and solid tumors. However, while analysts have published expectations for revenue and earnings growth and a potential move to profitability, the company is still loss making, relies on higher risk external funding and remains heavily tied to one lead product and key partners such as Janssen. Recent equity offerings and pipeline readouts add fresh information about both dilution and future potential, so there is more to this story than a simple high growth biotech label suggests.

Legend Biotech’s accelerating CAR-T story and early pipeline hints at more than a single product bet, but the real tension sits inside the 3 key rewards and 1 important warning sign that could redefine how you see its risk profile

The three stocks in this article are just a starting point, and the full screener has surfaced 250 more companies with similarly compelling growth setups and financial profiles in the Healthy high growth potential theme, which you can access through the Healthy high growth potential screener. Use Simply Wall St to identify and analyze the exact catalysts, earnings trajectories and balance sheet narratives that matter to you so you can focus on the highest conviction opportunities.

Take Control of Your Investment Journey

If Kulicke and Soffa Industries or any of these companies have caught your attention, register for FREE with Simply Wall St and add your companies to a Watchlist to monitor the share price against the fair value and track any new developments as they happen. Once you've made your move, manage your holdings with our Portfolio Command Center that filters out the noise to deliver only the most critical, actionable updates. Throughout your journey, our Community allows you to filter the best ideas from thousands of investor perspectives. By uncovering hidden catalysts and risks early, you'll accelerate your decision-making and stay one step ahead of the market.

Seeking Alternatives Before Momentum Flies

Fresh stock ideas can move from quiet to breakout quickly, and the strongest setups rarely stay under the radar for long. Scan these themes now and aim to get in early.

• Spot cash generative compounders early by running through a curated 45 high quality undervalued stocks while the valuation gap is still open and institutional money has not fully moved in.
• Consider structural shifts in digital assets by screening 19 cryptocurrency and blockchain stocks before capital moves in and re-rates the companies building blockchain and payment infrastructure.
• Look for earnings momentum in real assets by filtering 33 elite gold producer stocks while sentiment is mixed and producers are adjusting their fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.